OBJECTIVES: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment prolongs the progression-free survival of patients with advanced non-small-cell lung cancer harbouring EGFR mutations. This study aimed to evaluate the prognostic factors influencing survival after recurrence, and the effectiveness of EGFR-TKIs in patients with recurrent pulmonary adenocarcinoma after curative resection.
INTRODUCTION
Non-small-cell lung cancer (NSCLC) remains the most common cause of cancer-related mortality worldwide [1] . Surgical management is a potential curative option that can ensure long-term survival for patients with NSCLC. Despite improvement in early postoperative outcomes after curative resection, long-term survival remains poor, because of a high incidence of recurrence which continues to be the main cause of late deaths [2, 3] . Thus, prevention and effective treatment of recurrence are the most important strategies to improve long-term survival after curative resection. During the past two decades, several studies have demonstrated that adjuvant chemotherapy decreased recurrence and improved survival in patients after curative resection for NSCLC [4] . However, relatively few studies have examined the post-recurrence survival (PRS) and the effect of treatment modality after recurrence.
Over the course of the past 10 years, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment has become an important molecular-targeted therapy for treating advanced and recurrent NSCLC. Recent studies have found that somatic activating mutations in the EGFR tyrosine kinase domain in patients with pulmonary adenocarcinoma are associated with sensitivity to EGFR-TKIs [5, 6] . Subsequent randomized phase III trials confirmed a 70-80% objective response rate to EGFR-TKIs in patients with EGFR mutations, and EGFR-TKI therapy prolongs progressionfree survival of patients compared with a platinum-based regimen [7] [8] [9] . However, most of these studies focused on patients with advanced NSCLC, and the clinical benefit of EGFR-TKIs in patients with recurrent NSCLC is not yet fully understood.
In the present study, we evaluated the prognostic factors influencing survival after recurrence, and the effectiveness of EGFR-TKIs in patients with recurrent pulmonary adenocarcinoma after curative resection.
MATERIALS AND METHODS

Patients
This study protocol was reviewed and approved by the Institutional Review Board at Seoul National University Hospital (protocol number: H-1306-008-493). Between April 2000 and October 2010, EGFR mutations were prospectively evaluated in 594 patients who underwent curative surgical resection for pulmonary adenocarcinoma, and detected in 55.1% (327/594) of the patients. The basic technique for the detection of EGFR kinase domain mutations in tumour tissue by DNA sequencing methods has been previously described [10] . Among the 594 patients, 138 were identified with recurrence, and retrospectively reviewed. Demographic, operative, pathological and follow-up data for survival and recurrence were obtained through medical records and telephone interviews.
In general, our surgical policy was to achieve complete anatomical resection and to perform systemic mediastinal lymph node dissection. However, sublobar resection was performed in highrisk patients who were unable to tolerate lobectomy due to impaired cardiopulmonary function. In a highly select group of patients with synchronous solitary brain or adrenal metastasis, neurosurgical intervention or adrenalectomy was performed along with curative pulmonary resection. Neoadjuvant treatment was indicated for patients with bulky N2 diseases. Adjuvant platinum-based doublet chemotherapy was indicated for patients with pathological stage IIA or greater. Recurrences were treated based on their pattern, which included surgery, radiotherapy, chemotherapy or a combination of these; EGFR-TKIs were recommended as second-line palliative treatment. Prior to the establishment of a strong relationship between EGFR mutation status and response to EGFR-TKI treatment [5] [6] [7] , clinicians initiated EGFR-TKI treatment even with negative test results in patients of female gender, never-smoking status and having adenocarcinoma histology.
Postoperative surveillance was performed every 3 months during the first 2 years, biannually from the second to the fifth year and annually thereafter. Chest computed tomography (CT) was performed every 6 months, and an annual examination with positron emission tomography (PET)-CT was conducted simultaneously with chest CT. Recurrence was defined as the presence of disease after a disease-free interval (DFI) of more than 3 months after curative resection. The date of recurrence was defined as the date of the examination in which recurrence was documented. Locoregional recurrence was defined as relapse in an anatomically contiguous site or regional lymphatics of the primary tumour. Ipsilateral recurrent pulmonary adenocarcinomas that did not meet these criteria were classified as distant recurrences. Distant recurrence was defined as a recurrent tumour occurring apart from the treated primary tumour. A second primary tumour was defined when a patient presented with a different histological feature and with clinical manifestation consistent with a new primary tumour.
Statistical analysis
PRS was calculated from the date of recurrence to the date of death or the last follow-up date in all patients. Statistical analyses were performed using the SPSS package (version 21.0; IBM, Armonk, NY, USA). Normally distributed continuous data were expressed as mean ± standard deviations. Categorical data were expressed as counts and proportions. The PRS rate was estimated using the Kaplan-Meier method, and the statistical differences in variables were compared by log-rank statistics. Multivariable analysis was performed using the Cox proportional hazards model to identify independent prognostic factors. Potential prognostic factors with a P-value of less than 0.20 in the univariate analysis were included in the multivariable analysis. The factors were chosen by the forward selection method with the significance level for entry into the equation set at a P-value less than 0.05.
We further evaluated the predictive factors for EGFR-TKI effectiveness in patients treated with EGFR-TKI. Clinical responses to EGFR-TKIs were defined according to the Response Evaluation Criteria in Solid Tumors (RECIST) for patients with measurable disease [11] . Potential predictive factors with a P-value of less than 0.20 in the univariate analysis were included in the multivariable logistic regression. The factors were chosen by the forward selection method with the significance level for entry into the equation set at a P-value less than 0.05. A two-sided P-value of less than 0.05 was considered statistically significant.
RESULTS
Primary lung cancer characteristics
During a median follow-up of 51.2 (range 6.9-128.6) months, recurrent pulmonary adenocarcinoma developed in 138 (23.2%) patients. The clinical characteristics of the patients included in the study are summarized in Table 1 . The patients comprised 72 men (52.7%) and 66 women. The majority of patients underwent lobectomy (n = 119, 86.2%), followed by bilobectomy (n = 14, 10.1%), pneumonectomy (n = 3, 2.2%) and segmentectomy (n = 2, 1.4%). The pathological stages of patients were I in 48 patients, II in 19, III in 61 and IV in 10. Adjuvant chemotherapy was performed in 72 patients, and 20 received adjuvant radiotherapy.
Recurrent disease characteristics
The clinical characteristics of recurrent disease are summarized in Table 2 . The mean age of recurrence was 64.3 ± 10.5 years, and the median DFI from resection to recurrence was 16.0 (range 3.5-79.6) months. Initial recurrence was intrathoracic in 83 patients, extrathoracic in 30 and a combination of both in 25. Treatments after initial recurrence included surgery-based therapy for 29 patients, chemotherapy for 68, radiotherapy for 17 and a combination of chemotherapy and radiotherapy for 14. In the patients who received surgical resection for recurrence, initial recurrence was limited to the lungs in 16 patients, lymph nodes in 5, pleura in 3, chest wall in 1 and other solid organs in 4.
EGFR mutation status and prognostic factor EGFR mutations were detected in 52.9% (73/138) of the patients. The most common site of mutation was in exon 19 (exon 18 in 4, exon 19 in 40, exon 20 in 6 and exon 21 in 23 patients). EGFR mutations were frequently observed in female (P = 0.006) and never-smokers (P < 0.001) ( significant difference in clinical characteristics related to recurrence between patients with and those without EGFR mutations ( Table 2 ). The five-year overall survival rate of the 138 patients after initial resection was 51.1%. The 3-and 5-year PRS rates were 55.3 and 31.4%, respectively. Table 3 presents the multivariate analysis of all variables listed in Tables 1 and 2 . At initial recurrence, patients with never-smoking history (P = 0.012), surgical treatment for recurrence (P = 0.002) and EGFR mutations (P = 0.013) displayed better PRS. On the contrary, prior administration of adjuvant radiotherapy (P = 0.011) and a DFI of less than 1 year (P = 0.001) were associated with decreased PRS. The PRS curves for groups with different prognostic factors are plotted in Fig. 1 .
EGFR-TKI for recurrent disease
We next evaluated clinical responses to EGFR-TKIs for recurrent pulmonary adenocarcinoma in 80 patients with measurable disease who were treated with EGFR-TKIs (Table 4) . Patients with EGFR mutations had a higher response rate to EGFR-TKI compared to those without (74.1 vs 17.4%; P < 0.001). The median duration of EGFR-TKI treatment in patients with EGFR mutation was 13.4 (range 1-45) months, whereas patients with wild-type EFGR were treated for 2.2 (range 1-15) months (P < 0.001). In the multivariable analysis after adjusting confounding factors, EGFR mutation was the only independent predictor of response to EGFR-TKI (P < 0.001, Table 5 ). When treated with EGFR-TKIs, patients with EGFR mutations exhibited a better PRS (3-and 5-year survival rates after recurrence: 68.8 and 41.1%, respectively), compared with those without EGFR mutations (3-and 5-year survival rates after recurrence: 39.1 and 15.7%, respectively) (P = 0.017, Fig. 2 ).
DISCUSSION
Prognostic factors in patients with recurrent NSCLC have long been an overlooked area of research, although 30-75% of patients experience a recurrence, which contributes to low overall survival [2, 3, 12] . Considering that most recurrences present as a form of distant metastases [13] , systemic chemotherapy may play an important role in patients with postoperative recurrence. In the last decade, advances in genetics and molecular biology have identified EGFR-dependent pathways and yielded orally active, selective and reversible EGFR-TKIs to treat advanced NSCLC. After four recent East Asian randomized phase III trials [7] [8] [9] 14] demonstrated the superiority of gefitinib over platinum-based chemotherapy for advanced NSCLC, EGFR-TKIs have been accepted as a major treatment for advanced NSCLC. However, patients with postoperative recurrence may not be the focus of significant research interest, and the clinical roles of EGFR-TKIs for these patients have not yet been fully understood. Among these phase III studies, patients with postoperative recurrence were enrolled in two trials. In the WJTOG3405 study [8] , investigators failed to demonstrate the benefit of gefitinib in terms of progression-free survival in patients with postoperative recurrence. In the study by Maemondo et al. [9] , only a small subset of patients (20 of 230) with postoperative recurrence were included, and subgroup analysis based on disease characteristics, such as recurrence or advanced NSCLC, was not performed. The main reason for these patients not being eligible for clinical trials is that NSCLC patients with postoperative recurrence have different characteristics than those with advanced disease. Patients with postoperative recurrence are likely to have decreased pulmonary function and poor performance status as a result of prior surgical resection.
Recurrence following neoadjuvant/adjuvant treatment can theoretically be considered as the potential proliferation of tumour cells resistant to prior therapy [15] . Furthermore, selective re-resection may have a certain clinical role in the management of postoperative recurrence. Thus, analysing prognostic factors including primary tumour characteristics as well as recurrent disease characteristics should be considered essential for guiding treatment. This study has investigated the prognostic factors influencing PRS in patients with recurrent pulmonary adenocarcinoma after curative resection. Our results demonstrate that smoking status, prior administration of adjuvant radiotherapy, DFI, surgical treatment for recurrence and EGFR mutation were significant prognostic factors for survival after recurrence. Smoking status is a well-known predictive factor for chemotherapy agents as well as a prognostic factor for patients with early and advanced NSCLC [16, 17] . Tsao et al. analysed 1370 patients with advanced NSCLC and found that responses to chemotherapy among never, former and current smokers differed significantly (19 vs 8 vs 12%, P = 0.004), and 1-year survival rates of the never-smokers, former smokers and current smokers were 63, 42, and 43%, respectively (P < 0.0001) [16] . Other investigators have reported that high smoking index is associated with poor survival and increased risk of lung cancer recurrence [17] . Interestingly, some investigators have found that the administration of adjuvant radiotherapy is a poor prognostic factor for PRS [13, 18] . The reason for this is unclear, but as administration of additional therapy depends on primary lung cancer stage, adjuvant radiotherapy may surrogate pathological stage as a significant prognostic factor [13] . However, other investigators have found that once recurrence developed, pathological stage of the primary tumour was no longer a prognostic factor for survival after recurrence, which agrees with the current study [15, 19, 20] . The prognostic significance of adjuvant radiotherapy in patients with recurrent pulmonary adenocarcinoma should be further investigated in a large prospective study. Walsh et al. [21] have reported that DFI of more than 1 year was a favourable prognostic factor for overall survival and PRS in NSCLC after complete resection. DFI as a significant prognostic factor for PRS in NSCLC after curative resection has also been recently reported [13, 22] . In the current study, most recurrences (68.1%) were diagnosed within 2 years of surgery, and patients whose cancer recurred shortly after curative resection showed decreased PRS. Treatment modality for initial recurrence has been reported to be a prognostic factor for PRS. Some investigators have demonstrated the survival benefit of post-recurrence treatment for initial recurrence [13, 17, 23] . Sugimura et al. [13] reported that postrecurrence treatment was associated with improved PRS compared with supportive care alone. They also reported that surgical treatment of recurrence to the lung, other chest sites and brain showed the best PRS compared with nonsurgical treatments. In the current study, surgical resection for initial recurrence could significantly increase PRS in selected patients.
In the current study, we found 3-and 5-year PRS rates of 55.3 and 31.4%, respectively, which constitute an improved outcome over previous reports. Sugimura et al. reported that the 3-and 5-year PRS were 31 and 12%, respectively [13] . More recently, Shimada et al. [23] reported that the 2-year PRS was 51.4%. This improvement likely reflects that patients in the current study have more favourable prognostic factors compared with those of previous reports. We selected patients with adenocarcinoma histology, which is associated with female sex, never-smoking status and EGFR mutation, all of which are known to be better prognostic factors. In the current study, the frequency of EGFR mutation was 54.1%, and EGFR mutations were frequently observed in female and never-smokers. Considering the close relationship between EGFR mutation and these favourable factors, determining the 
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prognostic effect of EGFR mutation may be difficult. Eberhard et al. [24] have reported that EGFR mutations were associated with longer survival, irrespective of treatment, indicating that EGFR-mutated tumours have somewhat indolent disease behaviour. However, Kosaka et al. [25] reported that the presence of EGFR mutation itself was not a true prognostic factor after adjusting for sex, smoking status, tumour grade and stage. In the current study, EGFR mutation was an independent prognostic factor for PRS after adjusting for other prognostic factors in the multivariable analysis and was the only independent predictor for the response to EGFR-TKIs. The objective response rate was 72.1% in patients with EGFR mutations and 17.4% in those without EGFR mutation. This finding is in agreement with previous studies. Several studies have confirmed that the response rate to EGFR-TKI treatment in NSCLC patients with EGFR mutation is 70-80% [7] , and EGFR mutations have been regarded as predictive markers of response to EGFR-TKIs [5, 6] . In the current study, among patients treated with EGFR-TKI, patients with EGFR mutations showed better PRS than those without. This study has nonetheless, several limitations. First, as a retrospective single-institute study, the patient-selection and timetrend biases regarding the treatment for recurrent disease are unavoidable. A randomized clinical trial based on prognostic factors related to PRS will provide reliable evidence regarding the survival benefit of EGFR-TKI therapy. Secondly, although the criteria of Martini et al. [12] were used to distinguish lesions, uncertainty exists in differentiating a second primary lung cancer from recurrent lung cancer. In this study, tumours with N2-3 disease and a new lesion that appeared within the first 2 years following curative resection were considered to be recurrent disease.
In conclusion, smoking status, adjuvant radiotherapy, DFI, surgical treatment for the initial recurrence and EGFR mutations were independent prognostic factors for PRS in patients with recurrent pulmonary adenocarcinoma. Considering that EGFR mutations were the only independent predictors for response to EGFR-TKI treatment, selecting patients for EGFR-TKI therapy according to EGFR status might lead to a better prognosis in patients with postoperative recurrence.
